Consumers and health professionals are advised that Alphapharm Pty Ltd, in consultation with the TGA, is undertaking a recall of all batches of Tenofovir Disoproxil Emtricitabine Mylan 300/200 tablets due to the potential for broken/split tablets. If an affected tablet was not consumed entirely, this could result in an ineffective dose.
Tenofovir Disoproxil Emtricitabine Mylan 300/200 is prescribed:
- for the treatment of HIV-infected adults over the age of 18 years, in combination with other antiretroviral agents;
- in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.
Anyone with unexpired Tenofovir Disoproxil Emtricitabine Mylan 300/200 tablets should return them to their pharmacy for a refund.
Cracking is evident in these tablets.
Information for consumers
If you or someone you provide care for have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 please consult your treating physician for individual advice.
Patients should return the tablets to your pharmacist for a refund.
